Table 1.
Study population characteristics
| Variable | |
|---|---|
| Age, years, median (range) | 51 (44–83) |
| Gender, male, n | 41 |
| Risk factors for primary hepatic tumour, n | |
| Viral hepatitis C | 17 |
| Viral hepatitis B | 2 |
| Non-alcoholic steatohepatitis | 4 |
| Alcohol | 16 |
| Other | 7 |
| Body mass index, median (range) | 27.3 (20.1–39.0) |
| Body surface area, m2, median (range) | 1.91 (1.56–2.51) |
| Candidates for liver transplantation, n | 21 |
| Number of patients transplanted, n | 6 |
| Prior interventions for hepatic tumour, n | |
| Radiofrequency ablation | 6 |
| Histological diagnosis, n | 9 |
| Radiological diagnosis, n | 37 |
| Total number of TACE procedures | 102 |
| Number of TACE procedures/patient, median (range) | 1.5 (1–6) |
| Number of tumours/patient, median (range) | 1.0 (1–6) |
| Total number of TACE procedures, n | |
| Left lobe | 2 |
| Right lobe | 28 |
| Both lobes | 16 |
| Follow-up, months, median (range) | 17.1 (2–48) |
| Interval between TACE 1 and TACE 2, weeks, median (range) | 17 (9–40) |
| Interval between TACE 2 and TACE 3, weeks, median (range) | 22 (17–32) |
| Interval between TACE 3 and TACE 4, weeks, median (range) | 13 (12–14) |
TACE, transarterial chemoembolization.